Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific TAXUS V

This article was originally published in The Gray Sheet

Executive Summary

Paclitaxel-eluting stent clinical trial for 1,100 patients at 70 U.S. centers commences March 18. The study will evaluate the Taxus stent in patients considered to be at higher risk for restenosis than the 1,326 patients treated in TAXUS IV. On the same day, Boston Scientific submitted the second module of the device's PMA; the firm expects to file the fifth and final module in June and hopes for approval by year-end. FDA will prioritize review and approval of Taxus to provide competition for Johnson & Johnson/Cordis's Cypher, which is expected to be approved by the end of March (1"The Gray Sheet" March 17, 2002, In Brief)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT018069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel